Skip to main content
Premium Trial:

Request an Annual Quote

DNA Script Receives CE Mark for Syntax Enzymatic DNA Synthesis Platform

NEW YORK – DNA Script said on Tuesday that it has received CE marking for its Syntax enzymatic DNA synthesis platform, clearing the way for the benchtop DNA printer's commercial sales in Europe.

The CE marking covers the benchtop instrument, reagents, and consumables, the firm said.

The Syntax platform can currently synthesize up to 96 oligonucleotides of up to 60 nucleotides in length with a setup time of roughly 15 minutes. It can print 20mer oligos in approximately six hours and 60mer oligos in about 13 hours, enabling same-day and overnight synthesis, respectively. The system further purifies, quantifies, and normalizes oligos following synthesis, enabling their efficient integration into diverse workflows. Importantly, the entire process occurs in water, avoiding the need for toxic chemicals.

DNA Script, which recently raised $165 million in a Series C funding round, had released Syntax platforms to 41 academic, governmental, and commercial users through a targeted early-access program.

One early-access user, the Broad Institute, has been incorporating synthetic DNA from the Syntax platform into experiments involving developing 16S primer panels, rapid qPCR identification of selected microbes in a microbiome population survey project, and a DNA storage project.

"We can now deliver the Syntax system, with all the benefits of in-house DNA oligo synthesis, to European researchers," Thomas Ybert, DNA Script's cofounder and CEO, said in a statement. "By enabling rapid, on-site DNA production, the Syntax system accelerates lab workflows and helps scientists find answers faster."